Brief: Adagene Announces Clinical Data At Sitc 2022 On Anti-Ctla-4 Neobody, Adg116
10/11/2022 14:50
Nov 10 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES CLINICAL DATA AT SITC 2022 ON
ANTI-CTLA-4
NEOBODY™, ADG116, SHOWING DIFFERENTIATED SAFETY AND ANTI-TUMOR
ACTIVITY IN HEAVILY PRE-TREATED PATIENTS WITH DIFFICULT-TO-TREAT
TUMORS
* ADAGENE INC - INTERIM PHASE 1B/2 DATA REPORT SAFETY
PROFILE OF
ADG116 ACROSS DOSING LEVELS
* ADAGENE - PRELIMINARY UPDATE ON STUDY EVALUATING ADG116 IN
COMBINATION WITH PEMBROLIZUMAB SHOWS POTENT ACTIVITY IN MSS-CRC,
WITH NO DOSE LIMITING TOXICITIES
Source text for Eikon: ID:nGNX75xRC7
Further company coverage: 978y.F
((reuters.briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate